To retain its augmented reality filter creators, Snapchat has pledged $750,000 in payouts in 2020. It’s also expanded the use of product catalog ads, and now lets advertisers buy longer skippable ads.
At the same time, we are developing an Agile Governance Scorecard to help governments to assess and improve their regulatory system. In 2020, expect regulators to make big strides in improving their technology governance.
Finland’s new Working Hours Act, due to come into force in 2020, will give the majority of full-time employees the right to decide when and where they work for at least half of their working hours, in a move designed to help boost flexibility.
Westpac's chief economist Dominick Stephens and Westpac industry economist Paul Clark say they expect the impact of the coronavirus outbreak could knock 0.6 percentage points off New Zealand's March quarter GDP. They are now therefore predicting just 0.1% GDP growth for that quarter. They do, however, currently expect that tourism and other export activity will start recovering through the middle of 2020 and that as the level of GDP returns to normal levels, quarterly growth rates will be higher than normal.
There is a major change ahead for LinkedIn, the social network for the working world, now with 675 million members. Jeff Weiner, who has been leading the company as CEO for the past 11 years, is stepping down on June 1, 2020. His new role will be executive chairman. Ryan Roslansky, who is currently head of product, will be stepping up to the role of CEO, while Tomer Cohen, who had been under Roslansky, is stepping up to lead the product team.
Twitter noted that because of this headcount growth, it expects “total costs and expenses — which include cost of revenue and all operating expenses — to grow approximately 20 percent in 2020, ramping in absolute dollars over the course of the year.” Other important weights on its expenditures include adding a new data center this year.
We expect that CartaX, our private trading venue, will launch in 2020, pending regulatory approval. Private venture backed companies will list on CartaX so their shares can trade. Investors will want to buy and sell those shares. The problem is how do investors learn about the companies on CartaX and which ones to buy and sell?
Eli Lilly and Company (NYSE:LLY) offers an attractive opportunity for shareholders in 2020. The more than 140-year-old drug company has a few compelling metrics that demonstrate significant value for investors, including a strong return on equity (ROE), a modest dividend payout ratio, and continued profitability when compared with peers including GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE).
"We expect to recover in Q1 of 2020 about $5 million of the Q4 revenue shortfall," Daskal said, noting also that the firm does not anticipate it will be able to recover the remaining $15 million. The impact of the attack on overall expenses was broad-based, he said, including disruption to manufacturing and operations in general.
Biodesix announced Scott Hutton will become the firm's CEO, effective Jan. 1, 2020. Current CEO David Brunel will become the chairman and will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships, the company said. He is a cofounder of Biodesix and has led the firm for more than 13 years.
Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board.
Today, on Twist’s quarterly earnings call, the company also reported that its revenue increased 49.3% year-over-year to $17.2 million. Twist forecast revenue exceeding $80 million for 2020. On Thursday morning, shares of Twist Bioscience (NASDAQ: TWST) were trading at just below $27. By Friday afternoon, they were just above $32 a share, a rise of more than 18%, bringing its market capitalization to $1.1 billion.
As we enter 2020, investors, scientists and thought leaders are increasingly emphasizing the need to evolve the original concept of Femtech beyond reproductive health and what concerns the female reproductive organs, to that of a lenses through which we look into health issues that impact us differently, especially those that disproportionately affect women, such as Alzheimer’s or immunodeficiencies. The Femtech movement is progressing into a more intersectional territory, where otherwise non-female exclusive issues meet the specific needs of the female biology.